-
Publication Venue For
-
Reply to: "B vitamins for NASH: Use methylcobalamin, not cyanocobalamin"..
78:e35-e36.
2023
-
Reply to: The use of acoustic radiation force-based shear stiffness in non-alcoholic fatty liver disease.
56:996.
2012
-
Reply to "iL28B polymorphism and hepatitis C: A genetic marker of peginterferon-α sensitivity devoid from classical interferon-α side effects?".
56:742-743.
2012
-
Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
56:1336-1342.
2012
-
75 MYOFIBROBLASTS PROVIDE HEDGEHOG PARACRINE SIGNALS THAT DRIVE CHOLANGIOCYTES TO RECRUIT NKT CELLS TO PORTAL TRACTS.
50:S31-S32.
2009
-
The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States..
50:334-341.
2009
-
Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges..
50:184-194.
2009
-
Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients..
49:163-169.
2008
-
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma..
49:52-60.
2008
-
Fructose consumption as a risk factor for non-alcoholic fatty liver disease..
48:993-999.
2008
-
Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells..
48:98-106.
2008
-
Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia..
47:658-663.
2007
-
Important role of abnormal glycogen structure in the development of liver cirrhosis and progression to hepatocellular carcinoma in patients with glycogen storage disease type-III.
47:300-301.
2007
-
Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?.
46:492-498.
2007
-
Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis..
45:584-591.
2006
-
Interleukin-15 increases hepatic regenerative activity..
45:410-418.
2006
-
Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness..
44:971-983.
2006
-
Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes..
44:842-847.
2006
-
What impact does a specialized center for transplantation and heptobiliary disease have on post-graduate resident training of gastroenterologists and surgeons?.
44:659-662.
2006
-
Who should perform liver transplantation? Should that be the transplant surgeon, the hepatobilary surgeon, or the general surgeon? Part I: the transplant surgeon..
44:647-649.
2006
-
The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice..
44:411-421.
2006
-
A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients..
44:88-96.
2006
-
Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease..
43:1060-1066.
2005
-
Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma..
43:854-862.
2005
-
Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice..
43:317-323.
2005
-
Treatment of acute hepatitis C infection: more pieces of the puzzle?.
42:293-296.
2005
-
Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients..
41:935-942.
2004
-
The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients..
40:484-490.
2004
-
Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics..
38:681-687.
2003
-
Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C..
37:848-854.
2002
-
The role of endogenous heme oxygenase in the initiation of liver injury following limb ischemia/reperfusion..
36:624-630.
2002
-
Prognostic significance of glutamine synthetase expression in unifocal advanced hepatocellular carcinoma..
33:247-253.
2000
-
Increased ubiquitin immunoreactivity in hepatocellular carcinomas and precancerous lesions of the liver..
26:1266-1273.
1997
-
Non-parenchymal cell responses in paracetamol (acetaminophen)-induced liver injury..
20:537-541.
1994
-
Impact of resmetirom-mediated reductions in liver volume and steatosis compared with placebo on the quantification of fibrosis using second harmonic generation in a serial liver biopsy study
2022
-
LIVRQNac increases fatty acid oxidization in a primary human hepatocyte model of non-alcoholic steatohepatitis
2022
-
Aldafermin reduces hydrophobic bile acids in a 24-week, randomized, double-blind, placebo-controlled, multicenter study in patients with non-alcoholic steatohepatitis
2021
-
Atherosclerotic cardiovascular risk assessment in a 24-week, randomized, double-blind, placebo-controlled study of aldafermin
2021
-
Reduction in Fibrosis and Steatohepatitis Imaging and Biomarkers in a Phase 3 52 Week Resmetirom NASH Trial
2021
-
MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study
2020
-
Magnetic resonance imaging-proton density fat fraction (MRIPDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo-controlled phase 2 clinical trial
2020
-
Non-invasive tests of fibrosis and risk of liver-related complications: observations following successful sofosbuvir-based treatment in patients with HCV cirrhosis
2020
-
Positive topline results from a 24-week, randomized, doubleblind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis
2020
-
Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies
2019
-
MRI-PDFF response in MGL-3196 and placebo treated patients predicts reduction in ballooning and inflammation components of NAS and NASH resolution in a 36-week serial liver biopsy study
2019
-
PS-108-NGM, a novel activator of beta-Klotho/FGFR1c: A single dose significantly reduces steatosis (liver fat by MRI-PDFF), inflammation (ALT, AST) and fibrogenic activity (Pro-C3) in NAFLD subjects
2019
-
Early and late liver-related mortality following drug induced liver injury from amoxicillin-clavulanate
2018
-
JKB-121 in patients with nonalcoholic steatohepatitis: A phase 2 double blind randomized placebo control study
2018
-
MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study
2018
-
NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks
2018
-
Skeletal muscle index indicates mortality risk more accurately than psoas muscle index in patients with cirrhosis. From the FLEXIT consortium.
2018
-
NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients
2017
-
Correlation between the Hepatic Venous Pressure Gradient and Alpha-Smooth Muscle Actin (SMA) Expression in Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
2016
-
Effectiveness of Simeprevir-Containing Regimens among Patients with Chronic Hepatitis C Virus in Various Us Practice Settings: The Sonet Study
2016
-
Genome-Wide Association Study of Clinically Significant Portal Hypertension in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis
2016
-
INTEGRATED ANALYSIS OF SOF plus RBV OR LDV/SOF FOR THE TREATMENT OF GENOTYPE 4 CHRONIC HCV INFECTION
2016
-
Osteopontin Promotes Cholangiocyte Chemokine Secretion and Macrophage Accumulation in Murine Liver Fibrosis
2016
-
PNPLA3 Variants Confer an Increased Risk of Advanced Fibrosis Due to Non-Alcoholic Steatohepatitis
2016
-
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study
2016
-
CROSS-TALK BETWEEN IL13 AND HEDGEHOG PATHWAYS CONTRIBUTES TO SCHISTOSOMIASIS MANSONI FIBROSIS
2015
-
P0469 : Markers of tissue repair and cellular aging are increased in liver tissue of patients with dual chronic HIV/HCV infections
2015
-
P0826 : Effectiveness of simeprevir (SMV)-containing regimens among patients with chronic hepatitis C virus (HCV) in various us practice settings: Interim analysis of the sonet study
2015
-
P0935 : Non-alcoholic steatohepatitis (NASH): 2 complementary dietary mouse models
2015
-
P1131 : Autoimmune hepatitis-like drug induced liver injury
2015
-
P1353 : A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection : The phase 3 ION-4 study
2015
-
P1173 THE IMPACT OF HIV CO-INFECTION ON RATES AND SEVERITY OF ANEMIA OCCURRING DURING TREATMENT WITH SOFOSBUVIR-CONTAINING HCV REGIMENS: A POOLED ANALYSIS
2014
-
P612 OSTEOPONTIN NEUTRALIZATION ABROGATES THE LIVER PROGENITOR CELL RESPONSE AND FIBROGENIC OUTCOMES IN MICE
2014
-
242 HYPONATREMIA IN HOSPITALIZED PATIENTS WITH CIRRHOSIS: INTERIM DATA FROM AN OBSERVATIONAL, PROSPECTIVE, MULTI-CENTER, GLOBAL HYPONATREMIA REGISTRY
2013
-
312 PRAZOSIN AN ALPHA1 ADRENOCEPTOR ANTAGONIST PROTECTS LIVER FROM ACETAMINOPHEN INDUCED ACUTE LIVER INJURY AND EXPANDS THE PROGENITOR CELL POPULATION
2013
-
1364 DIAGNOSING HEPATOTOXICITY ATTRIBUTABLE TO HERBAL & DIETARY SUPPLEMENTS (HDS): TEST-RETEST RELIABILITY OF A NOVEL CAUSALITY ASSESSMENT TOOL
2012
-
331 ACUTE LIVER FAILURE IN MICE FOLLOWING DELETION OF CFLIP - A KEY ROLE OF APOPTOSIS SIGNALING PATHWAYS IN TISSUE HOMEOSTASIS
2012
-
376 STATINS INDUCE SENESCENCE OF ACTIVATED HSC BY INHIBITION OF THE HEDGEHOG PATHWAY
2012
-
379 THREE PHENOTYPICALLY AND FUNCTIONALLY DISTINCT MONOCYTE SUBSETS AND THEIR ROLE IN HUMAN LIVER FIBROSIS
2012
-
681 HYPONATREMIA IN HOSPITALIZED PATIENTS WITH CIRRHOSIS: INTERIM DATA FROM AN OBSERVATIONAL, PROSPECTIVE, MULTI-CENTER, GLOBAL HYPONATREMIA REGISTRY INDICATES THAT HYPONATREMIA IS FREQUENTLY NOT TREATED
2012
-
884 EXPLORATION OF SERUM ADIPOCYTOKINE ASSOCIATIONS WITH IL28B GENOTYPE IN CHRONIC HEPATITIS C
2012
-
1334 DYSREGULATION OF HOST INNATE IMMUNITY IN HCV GENOTYPE 1 INFECTED IL28B CT/TT HAPLOTYPE PATIENTS WITH DEPRESSED VIRAL KINETICS AND THERAPEUTIC RESPONSE
2011
-
144 SYNERGISTIC ROLES OF HEPATIC ENCEPHALOPATHY AND OBSTRUCTIVE SLEEP APNEA IN DISTURBANCE OF SLEEP ARCHITECTURE IN PATIENTS WITH CIRRHOSIS
2011
-
674 HEPATOCYTE-SPECIFIC DELETION OF CFLIP ENHANCES LIVER INJURY FROM STREPTOZOTOCIN-INDUCED HYPERGLYCEMIA INVOLVING ACTIVATION OF JNK
2011
-
869 COFFEE CONSUMPTION INCREASES HEPATIC EXPRESSION OF CYTOCHROME P450S AND SIGNIFICANTLY REDUCES LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
2011
-
DELETION OF CFLIP IN HEPATOCYTES AUGMENTS CCL4-INDUCED LIVER INJURY INVOLVING ACTIVATION OF MITOGEN ACTIVATED PROTEIN KINASES
2011
-
1179 INTERFERON LAMBDA GENOTYPE AND LOW SERUM LDL CHOLESTEROL LEVELS IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION
2010
-
307 HIGH PREVALENCE OF PRE-EXISTING ANTIBODIES AGAINST POLYETHYLENE GLYCOL (PEG) IN HEPATITIS C (HCV) PATIENTS WHICH IS NOT ASSOCIATED WITH IMPAIRED RESPONSE TO PEG-INTERFERON
2010
-
69 THE CASPASE-8 HOMOLOGUE FLIP MODULATES HEPATOCARCINOGENESIS IN MICE
2010
-
46 ABLATION OF C-FLIP AUGMENTS CD95- AND GALACTOSAMINE/LPS-INDUCED LIVER INJURY THROUGH ACTIVATION OF C-JUN N-TERMINAL KINASE (JNK)
2008
-
482 ACETYLCHOLINE INDUCES FIBROGENIC EFFECTS IN HUMAN PRIMARY HEPATIC STELLATE CELLS
2008